Fairvalue-Calculator Fairvalue-Calculator
EN DE

Organogenesis Holdings (ORGO) Fair Value & Analysis

Healthcare · US · Market cap $314M

Price$2.44
Fair Value$6.33
Upside+159.4%
Quality95/100
Evidence: High Range $2.92 – $7.91

Fair value as of: Jun 25, 2026

Analysis

Organogenesis Holdings (ORGO) currently trades at $2.44, while our model-based Fair Value estimate is $6.33 — implying the stock looks roughly 159.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat …

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is Organogenesis Holdings (ORGO) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $6.33 versus a price of $2.44 — about +159% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ORGO?
Our 21-model fair value for Organogenesis Holdings is $6.33 (as of Jun 25, 2026), built from audited fundamentals. The current price is $2.44.
What is the quality score of ORGO?
Organogenesis Holdings has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.